LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 29 filers reported holding LYRA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70 | -5.4% | 18 | 0.0% | 0.00% | – |
| Q2 2023 | $74 | -95.7% | 18 | -97.9% | 0.00% | – |
| Q1 2023 | $1,714 | -83.9% | 853 | -74.9% | 0.00% | – |
| Q4 2022 | $10,667 | -28.9% | 3,397 | +9.8% | 0.00% | – |
| Q3 2022 | $15,000 | +36.4% | 3,094 | +53.0% | 0.00% | – |
| Q2 2022 | $11,000 | – | 2,022 | +11133.3% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 18 | -99.6% | 0.00% | – |
| Q4 2021 | $18,000 | – | 4,070 | +22511.1% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 18 | -96.8% | 0.00% | – |
| Q2 2021 | $5,000 | -84.4% | 567 | -79.4% | 0.00% | – |
| Q1 2021 | $32,000 | -22.0% | 2,754 | -23.9% | 0.00% | – |
| Q4 2020 | $41,000 | +355.6% | 3,617 | +326.5% | 0.00% | – |
| Q3 2020 | $9,000 | -52.6% | 848 | -50.6% | 0.00% | – |
| Q2 2020 | $19,000 | – | 1,716 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $3,572,275 | 0.74% |
| Perceptive Advisors | 9,146,730 | $18,384,927 | 0.54% |
| PURA VIDA INVESTMENTS, LLC | 1,996,972 | $4,013,914 | 0.41% |
| VR Adviser, LLC | 924,170 | $1,857,582 | 0.36% |
| Nantahala Capital Management | 2,220,830 | $4,463,868 | 0.34% |
| Ikarian Capital, LLC | 343,685 | $711,427 | 0.16% |
| Soleus Capital Management, L.P. | 592,417 | $1,190,758 | 0.12% |
| Clearline Capital LP | 119,128 | $239,448 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $303,876 | 0.01% |
| Tower Research Capital LLC (TRC) | 9,972 | $20 | 0.00% |